Xifarix 550 Tablet contains Rifaximin 550 mg, a broad-spectrum, non-systemic antibiotic primarily indicated for the treatment of gastrointestinal infections caused by susceptible strains of bacteria. Rifaximin acts by inhibiting bacterial RNA synthesis through binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby exerting a bactericidal effect. Due to its minimal systemic absorption, Xifarix 550 is particularly effective in targeting intestinal pathogens with limited systemic exposure, reducing the risk of systemic side effects. It is commonly prescribed for the management of travelers’ diarrhea caused by non-invasive strains of Escherichia coli, as well as for the treatment of hepatic encephalopathy to reduce the risk of recurrent episodes by decreasing intestinal ammonia-producing bacteria. Additionally, Xifarix 550 may be utilized in the treatment of irritable bowel syndrome with diarrhea (IBS-D) and small intestinal bacterial overgrowth (SIBO). The recommended dosage and duration of therapy should be determined by a healthcare professional based on the specific indication and patient condition. Patients should be advised to complete the full course of therapy to prevent bacterial resistance. Contraindications include hypersensitivity to rifaximin or other rifamycin derivatives. Common adverse effects are generally mild and may include nausea, abdominal pain, and headache.